Smith & Nephew stock holds near 52 week range

Smith & Nephew plc (US83175M2052) was quoted at USD 95.42 on September 23, 2026, after opening at USD 95.02, according to the Reuters market page for the company. The price provides the current market anchor while the latest available operating context points to fiscal 2025 revenue of USD 6.16 billion.

Revenue reached USD 6.16 billion

A September 23, 2026 company comparison published by The Brand Hopper states that Smith & Nephew generated USD 6.16 billion in group revenue in fiscal 2025, compared with USD 5.81 billion in fiscal 2024. That represents growth of 6.1 percent and gives investors a dated measure of the group's recent operating scale.

The business is described across orthopaedics, sports medicine and ear, nose and throat products, and advanced wound management, with the three divisions covering joint replacement, trauma, soft-tissue repair and wound-care therapies, according to The Brand Hopper on September 23, 2026.

Market data sets the benchmark

The September 23, 2026 quotation of USD 95.42 compares with an opening price of USD 95.02, a difference of USD 0.40 between the two market observations. Reuters identifies Smith & Nephew's primary share listing as the London market, while the SNN instrument is the US-traded security identified in the request.

For investors, the useful comparison is therefore between the dated quote and the latest reported revenue trajectory: the share observation is intraday market data, while the 6.1 percent figure describes the change from fiscal 2024 to fiscal 2025. These figures measure different time horizons and should not be treated as a direct performance comparison.

Stock reference remains USD 95.42

Smith & Nephew was quoted at USD 95.42 on September 23, 2026, with an opening price of USD 95.02. The fiscal 2025 revenue figure of USD 6.16 billion and the 6.1 percent year-over-year increase remain the central operating reference points.

More news and analyses on Smith and Nephew stock